Translational Research and Interventional Oncology Research Program
The Translational Research and Interventional Oncology Research Program is an integrated multi-disciplinary program that provides the opportunity for clinical investigators and laboratory scientists to collaboratively address the rapidly changing landscape of cancer therapy. The program traverses multiple disciplines, including precision oncology, immuno-oncology, cellular therapy, and immune-toxicity.
RESEARCH THEMES
The Translational Research and Interventional Oncology program is dedicated to translating our understanding of the molecular mechanisms of oncogenesis and tumor progression into novel therapeutic strategies for patients with cancer.
Early Phase Trials
Developing early phase clinical trials for therapies directed at genetic changes in tumors and for novel immunotherapeutic combinations
Therapeutic Resistance
Investigating why some tumors become resistant to immunotherapies and genetically targeted therapies and developing new strategies to prevent and overcome resistance
Immune & Cellular Therapy
Applying and enhancing innovative immunotherapeutic strategies and cellular therapies for cancer
Meet the Program Members
The Translational Research and Interventional Oncology Program is the largest of the cancer center's formal research programs, representing a range of clinical and translational cancer research areas. The program is led by Douglas Johnson, M.D., M.S.C.I., Kristen K. Ciombor, M.D., M.S.C.I and Eben Rosenthal, M.D.
